Theravance (THRX) Positive Results from Chronic Pain Syndrome Study, Alexza Pharmaceuticals (ALXA) A

chartstockalert Theravance Inc. (THRX)

Fibromyalgia has been estimated to affect approximately 5 million individuals in the United States. It is the most common musculoskeletal condition after osteoarthritis. Still, it is often misdiagnosed and misunderstood. Its characteristics include widespread muscle and joint pain and fatigue, as well as other symptoms. Fibromyalgia can lead to depression and social isolation.

Although fibromyalgia is often considered an arthritis-related condition, it is not truly a form of arthritis (a disease of the joints) because it does not cause inflammation or damage to the joints, muscles, or other tissues. Like arthritis, however, fibromyalgia can cause significant pain and fatigue, and it can interfere with a person’s ability to carry on daily activities.

THRX reported positive results from a Phase 2 study of TD-9855 in patients with fibromyalgia

TD-9855, discovered by THRX, is an investigational norepinephrine and serotonin reuptake inhibitor for the treatment of central nervous system conditions such as chronic pain and Attention-Deficit/Hyperactivity Disorder.

The study demonstrated statistically significant and clinically meaningful improvements in the primary and secondary endpoints at the 20 mg dose of TD-9855, which was generally well tolerated and, compared with placebo, significantly improved pain as well as other symptoms commonly associated with fibromyalgia.

THRX is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. It is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain.

More about Theravance Inc. (THRX) at

** Crown Equity Holdings Inc. (CRWE)

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

CRWE is currently developing its CRWE Network (, a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada. CRWE‘s local and national coupon distribution application “Roxzu” ( is in its product development stage and is currently online being test marketed for the Las Vegas, Nevada region. Roxzu’s restaurant dining app will also features live dining and restaurant deals.

After testing and review, the application is expected to be integrated in all the geo community CRWE-PR network sites by the end of the 2Q of 2014.

CRWE has plans to expand the application to include auto repairs, realtors, bars, movie theaters, retailers, golf courses, auto dealerships and any other variety of businesses existing within a community. The CRWE Network, based on the momentum the industry has taken in positioning itself for additional grow in the future, is in the process of building an online medical marijuana informational and directory search platform ( The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 500th community website in the U.S., associated with 2042 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada

CRWE Network’s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums, while providing micro community news, information and business directory content.

More about Crown Equity Holdings Inc. (CRWE) at or the CRWE Network at

** Alexza Pharmaceuticals Inc. (ALXA)

ALXA said that ADASUVE(R) inhalation powder, pre-dispensed (loxapine) is now available in the Nordic countries (Sweden, Norway, Denmark and Finland).

Grupo Ferrer Internacional, S.A. is commercializing ADASUVE in the Nordic countries through a distribution agreement with Medivir AB. Ferrer is ALXA's commercial partner for ADASUVE in the Europe, Latin America and the Commonwealth of Independent States countries.

ALXA and Ferrer estimate that as many as 8 million adults in the EU alone suffer from schizophrenia or bipolar disorder. Agitation is a common symptom for these patients, characterized by feelings of distress, anxiety and loss of control.

ALXA received marketing authorization for ADASUVE from the European Commission in February 2013. ADASUVE is the first inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder authorized for marketing in the EU.

ADASUVE combines ALXA's proprietary Staccato system with loxapine, an antipsychotic medicinal product. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in intravenous-like pharmacokinetics and rapid systemic effects.

ALXA is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.

More about Alexza Pharmaceuticals Inc. (ALXA) at

** Flextronics International Ltd. (FLEX)

Keep a close eye on FLEX. The company reported strong performance on its financial results.

For the fourth quarter fiscal 2014, FLEX posted net sales of $6.7 billion, higher than its previously provided revenue guidance of $5.9 billion to $6.3 billion, and adjusted earnings per diluted share of $0.24, also higher than the company's previously provided guidance of $0.18 to $0.22.

According to its guidance for the first quarter ending June 27, 2014, FLEX expects revenue to be in the range of $6.0 to $6.5 billion and adjusted EPS is expected to be in the range of $0.20 to $0.24 per diluted share.

FLEX is a leading end-to-end supply chain solutions company that delivers design, engineering, manufacturing and logistics services to a range of industries and end-markets, including data networking, telecom, enterprise computing and storage, industrial, capital equipment, appliances, automation, medical, automotive, aerospace and defense, energy, mobile, computing and other electronic product categories

More about Flextronics International Ltd. (FLEX) at


Read Full Disclaimer at

1.5.14 10:53


bisher 0 Kommentar(e)     TrackBack-URL

E-Mail bei weiteren Kommentaren
Informationen speichern (Cookie)

Die Datenschuterklärung und die AGB habe ich gelesen, verstanden und akzeptiere sie. (Pflicht Angabe)

 Smileys einfügen